U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C10H13NO4
Molecular Weight 211.2145
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of METHYLDOPA ANHYDROUS

SMILES

C[C@](N)(CC1=CC(O)=C(O)C=C1)C(O)=O

InChI

InChIKey=CJCSPKMFHVPWAR-JTQLQIEISA-N
InChI=1S/C10H13NO4/c1-10(11,9(14)15)5-6-2-3-7(12)8(13)4-6/h2-4,12-13H,5,11H2,1H3,(H,14,15)/t10-/m0/s1

HIDE SMILES / InChI

Molecular Formula C10H13NO4
Molecular Weight 211.2145
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Methyldopate hydrochloride [levo-3-(3,4-dihydroxyphenyl)-2-methylalanine, ethyl ester hydrochloride] is the ethyl ester of methyldopa, supplied as the hydrochloride salt with a molecular weight of 275.73. Methyldopate hydrochloride is more soluble and stable in solution than methyldopa and is the preferred form for intravenous use. Methyldopate hydrochloride is an alpha adrenergic agonist that has both central and peripheral nervous system effects. Its primary clinical use is as an antihypertensive agent.

CNS Activity

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ALDOMET

Approved Use

INDICATION AND USAGE: Hypertension.

Launch Date

-2.21961601E11
Primary
ALDOMET

Approved Use

INDICATION AND USAGE: Hypertension.

Launch Date

-2.21961601E11
Primary
ALDOMET

Approved Use

INDICATION AND USAGE: Hypertension.

Launch Date

-2.21961601E11
Primary
Methyldopate hydrochloride

Approved Use

Hypertension, when parenteral medication is indicated. The treatment of hypertensive crises may be initiated with Methyldopate HCl Injection.

Launch Date

8.1233281E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
771.3 ng/mL
250 mg single, oral
dose: 250 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
METHYLDOPA plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
4.54 μg × h/mL
100 mg single, intravenous
dose: 100 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
METHYLDOPA plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
5352.9 ng × h/mL
250 mg single, oral
dose: 250 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
METHYLDOPA plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.28 h
100 mg single, intravenous
dose: 100 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
METHYLDOPA plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
12.6 h
250 mg single, oral
dose: 250 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
METHYLDOPA plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
85%
100 mg single, intravenous
dose: 100 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
METHYLDOPA plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
2.5 g single, oral
Dose: 2.5 g
Route: oral
Route: single
Dose: 2.5 g
Sources:
unknown, 19
n = 1
Health Status: unknown
Age Group: 19
Sex: M
Population Size: 1
Sources:
Other AEs: Coma...
Other AEs:
Coma (grade 1)
Sources:
2326 mg multiple, oral (mean)
Recommended
Dose: 2326 mg
Route: oral
Route: multiple
Dose: 2326 mg
Sources:
unhealthy, 36-68
n = 30
Health Status: unhealthy
Condition: hypertension
Age Group: 36-68
Sex: M+F
Population Size: 30
Sources:
Disc. AE: Depression, Tiredness...
AEs leading to
discontinuation/dose reduction:
Depression (2 patients)
Tiredness (2 patients)
Diarrhoea (1 patient)
Rash (1 patient)
Blackout (1 patient)
Sources:
250 mg 4 times / day multiple, oral
Recommended
Dose: 250 mg, 4 times / day
Route: oral
Route: multiple
Dose: 250 mg, 4 times / day
Sources:
unhealthy
n = 39
Health Status: unhealthy
Condition: hypertension
Sex: M+F
Population Size: 39
Sources:
Other AEs: Somnolence, Dry mouth...
Other AEs:
Somnolence (15 patients)
Dry mouth (12 patients)
Malaise (6 patients)
Constipation (5 patients)
Anorexia (5 patients)
Diarrhoea (3 patients)
Depression (2 patients)
Weight gain (2 patients)
Mental confusion (1 patient)
Postural hypotension (1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Coma grade 1
2.5 g single, oral
Dose: 2.5 g
Route: oral
Route: single
Dose: 2.5 g
Sources:
unknown, 19
n = 1
Health Status: unknown
Age Group: 19
Sex: M
Population Size: 1
Sources:
Blackout 1 patient
Disc. AE
2326 mg multiple, oral (mean)
Recommended
Dose: 2326 mg
Route: oral
Route: multiple
Dose: 2326 mg
Sources:
unhealthy, 36-68
n = 30
Health Status: unhealthy
Condition: hypertension
Age Group: 36-68
Sex: M+F
Population Size: 30
Sources:
Diarrhoea 1 patient
Disc. AE
2326 mg multiple, oral (mean)
Recommended
Dose: 2326 mg
Route: oral
Route: multiple
Dose: 2326 mg
Sources:
unhealthy, 36-68
n = 30
Health Status: unhealthy
Condition: hypertension
Age Group: 36-68
Sex: M+F
Population Size: 30
Sources:
Rash 1 patient
Disc. AE
2326 mg multiple, oral (mean)
Recommended
Dose: 2326 mg
Route: oral
Route: multiple
Dose: 2326 mg
Sources:
unhealthy, 36-68
n = 30
Health Status: unhealthy
Condition: hypertension
Age Group: 36-68
Sex: M+F
Population Size: 30
Sources:
Depression 2 patients
Disc. AE
2326 mg multiple, oral (mean)
Recommended
Dose: 2326 mg
Route: oral
Route: multiple
Dose: 2326 mg
Sources:
unhealthy, 36-68
n = 30
Health Status: unhealthy
Condition: hypertension
Age Group: 36-68
Sex: M+F
Population Size: 30
Sources:
Tiredness 2 patients
Disc. AE
2326 mg multiple, oral (mean)
Recommended
Dose: 2326 mg
Route: oral
Route: multiple
Dose: 2326 mg
Sources:
unhealthy, 36-68
n = 30
Health Status: unhealthy
Condition: hypertension
Age Group: 36-68
Sex: M+F
Population Size: 30
Sources:
Mental confusion 1 patient
250 mg 4 times / day multiple, oral
Recommended
Dose: 250 mg, 4 times / day
Route: oral
Route: multiple
Dose: 250 mg, 4 times / day
Sources:
unhealthy
n = 39
Health Status: unhealthy
Condition: hypertension
Sex: M+F
Population Size: 39
Sources:
Postural hypotension 1 patient
250 mg 4 times / day multiple, oral
Recommended
Dose: 250 mg, 4 times / day
Route: oral
Route: multiple
Dose: 250 mg, 4 times / day
Sources:
unhealthy
n = 39
Health Status: unhealthy
Condition: hypertension
Sex: M+F
Population Size: 39
Sources:
Dry mouth 12 patients
250 mg 4 times / day multiple, oral
Recommended
Dose: 250 mg, 4 times / day
Route: oral
Route: multiple
Dose: 250 mg, 4 times / day
Sources:
unhealthy
n = 39
Health Status: unhealthy
Condition: hypertension
Sex: M+F
Population Size: 39
Sources:
Somnolence 15 patients
250 mg 4 times / day multiple, oral
Recommended
Dose: 250 mg, 4 times / day
Route: oral
Route: multiple
Dose: 250 mg, 4 times / day
Sources:
unhealthy
n = 39
Health Status: unhealthy
Condition: hypertension
Sex: M+F
Population Size: 39
Sources:
Depression 2 patients
250 mg 4 times / day multiple, oral
Recommended
Dose: 250 mg, 4 times / day
Route: oral
Route: multiple
Dose: 250 mg, 4 times / day
Sources:
unhealthy
n = 39
Health Status: unhealthy
Condition: hypertension
Sex: M+F
Population Size: 39
Sources:
Weight gain 2 patients
250 mg 4 times / day multiple, oral
Recommended
Dose: 250 mg, 4 times / day
Route: oral
Route: multiple
Dose: 250 mg, 4 times / day
Sources:
unhealthy
n = 39
Health Status: unhealthy
Condition: hypertension
Sex: M+F
Population Size: 39
Sources:
Diarrhoea 3 patients
250 mg 4 times / day multiple, oral
Recommended
Dose: 250 mg, 4 times / day
Route: oral
Route: multiple
Dose: 250 mg, 4 times / day
Sources:
unhealthy
n = 39
Health Status: unhealthy
Condition: hypertension
Sex: M+F
Population Size: 39
Sources:
Anorexia 5 patients
250 mg 4 times / day multiple, oral
Recommended
Dose: 250 mg, 4 times / day
Route: oral
Route: multiple
Dose: 250 mg, 4 times / day
Sources:
unhealthy
n = 39
Health Status: unhealthy
Condition: hypertension
Sex: M+F
Population Size: 39
Sources:
Constipation 5 patients
250 mg 4 times / day multiple, oral
Recommended
Dose: 250 mg, 4 times / day
Route: oral
Route: multiple
Dose: 250 mg, 4 times / day
Sources:
unhealthy
n = 39
Health Status: unhealthy
Condition: hypertension
Sex: M+F
Population Size: 39
Sources:
Malaise 6 patients
250 mg 4 times / day multiple, oral
Recommended
Dose: 250 mg, 4 times / day
Route: oral
Route: multiple
Dose: 250 mg, 4 times / day
Sources:
unhealthy
n = 39
Health Status: unhealthy
Condition: hypertension
Sex: M+F
Population Size: 39
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer

Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
likely
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Delayed hepatotoxicity from methyldopa.
1975 Dec
Letter: side effects of methyldopa.
1975 May 31
Dihydroergotamine: an effective treatment for postural hypotension due to antihypertensive drugs (ganglion-blocking agents excepted).
1976
Dementia induced by methyldopa with haloperidol.
1976 May 27
Cardiac hypertrophy and antihypertensive therapy.
1977 Sep
Acute reactive hepatitis in pregnancy induced by alpha-methyldopa.
1997 Oct
Drug-associated acute pancreatitis: twenty-one years of spontaneous reporting in The Netherlands.
1999 Sep
The effect of methyldopa on retinal artery circulation in pre-eclamptic gravidae.
2000 Jun
Antihypertensive treatment decreased serum leptin levels in severe preeclampsia during pregnancy.
2001
Risk factors for male breast cancer--a case-control study from Scandinavia.
2001
[Drug-induced hemolytic anemia].
2001 Aug
Ddc and amd sequences resolve phylogenetic relationships of Drosophila.
2001 Aug
Effect of methyldopa on renal function in rats with L-NAME-induced hypertension in pregnancy.
2001 Aug
Effect of alpha-methyldopa on pentoxyresorufin O-dealkylation in liver microsomes from rats treated with phenobarbital.
2001 Aug 1
Effect of phenobarbital and spironolactone treatment on the oxidative metabolism of antipyrine by rat liver microsomes.
2001 Jan-Feb
[Enantiomeric separation of drugs based on macrocyclic antibiotics].
2001 Jul
Drug interference in clinical chemistry: recommendation of drugs and their concentrations to be used in drug interference studies.
2001 Jul
NHBPEP report on high blood pressure in pregnancy: a summary for family physicians.
2001 Jul 15
Pharmacological treatment of severe hypertension in pregnancy and the role of serotonin(2)-receptor blockers.
2001 Mar
Pharmacokinetic and pharmacodynamic alterations of methyldopa in rats with aortic coarctation. A study using microdialysis.
2001 Nov
Juxtaglomerular cell tumor in pregnancy.
2001 Nov
Involvement of imidazoline receptors in the baroreflex effects of rilmenidine in conscious rabbits.
2001 Sep
The immune haemolytic anaemias: a century of exciting progress in understanding.
2001 Sep
Excretion of antihypertensive medication into human breast milk: a systematic review.
2002
Methyldopa versus no drug treatment in the management of mild pre-eclampsia.
2002 Apr
Immune-mediated drug-induced liver disease.
2002 Aug
Effects of six anti-hypertensive medications on cognitive performance.
2002 Aug
Calcium channel blocker, nimodipine, for the treatment of bipolar disorder during pregnancy.
2002 Dec
Brain catecholamine metabolism in catechol-O-methyltransferase (COMT)-deficient mice.
2002 Jan
C4 deficiency state in antiphospholipid antibody-related recurrent preeclampsia evolving into systemic lupus erythematosus.
2002 Jul
The treatment of hypertension in pregnancy.
2002 May
Analysis of L-dopa in human serum.
2002 Nov
Pathophysiology and treatment of hot flashes.
2002 Nov
Spectrophotometric investigations of the assay of physiologically active catecholamines in pharmaceutical formulations.
2002 Nov-Dec
Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy volunteers.
2003
Shifting trends in the pharmacologic treatment of hypertension in a Nigerian tertiary hospital: a real-world evaluation of the efficacy, safety, rationality and pharmaco-economics of old and newer antihypertensive drugs.
2003 Apr
Antihypertensive drug-associated sexual dysfunction: a prescription analysis-based study.
2003 Apr-May
Angiotensin II-receptor-antagonists: further evidence of fetotoxicity but not teratogenicity.
2003 Aug
Pharmacokinetic profile of methyldopa in the brain of sinaortic-denervated rats.
2003 Jul
Antihypertensive efficacy of moxonidine in primary care: a 'real-life' study.
2003 Jul-Aug
Blood pressure response to out-patient drug treatment of hypertension in 1973-1993 at Korle-Bu Teaching Hospital, Accra, Ghana.
2003 Jun
Catechol-O-methyltransferase inhibition in erythrocytes and liver by BIA 3-202 (1-[3,4-dibydroxy-5-nitrophenyl]-2-phenyl-ethanone).
2003 Jun
Replacement of antipsychotic and antiepileptic medication by L-alpha-methyldopa in a woman with velocardiofacial syndrome.
2003 Mar
[Methyldopa in therapy of hypertension in pregnant women].
2004 Feb
Pheochromocytoma during pregnancy: laparoscopic and conventional surgical treatment of two cases.
2004 Feb
Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society.
2004 Jan-Feb
[Centrally-acting antihypertensive drugs].
2004 Mar
[Hypertension in pregnancy].
2004 Mar
Differential modulation by estrogen of alpha2-adrenergic and I1-imidazoline receptor-mediated hypotension in female rats.
2004 Oct
Inadequate control of blood pressure in Nigerians with diabetes.
2004 Winter
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: When control has been obtained, oral therapy with tablets may be substituted for intravenous therapy, starting with the same dosage schedule used for the parenteral route. The effectiveness and anticipated responses are described in the circular for tablets.
Initial: 250 mg PO q8-12hr for 2 days, increase q2Days PRN Maintenance: 250-1000 mg/day divided q6-12hr PO, usually no more than 3 g/day IV (methyldopate): 250-1000 mg infusion over 30-60 minutes q6-8hr PRN; no more than 4 g/day
Route of Administration: Other
Human uterine microvascular endothelial cells (UtMVEC) (PromoCell, Heidelberg, Germany) were cultured in EGM-2- MV medium (Lonza, Basel, Switzerland) until about 80% confluent. Cells from passage 4-8 were used in this study. Tissue culture plates (24-wells) were coated with undiluted Matrigel (300 μL/well; In Vitro Technologies, Noble Park, Vic., Australia) and polymerized for 30 minutes at 37°C. UtMVECs (100 000 cells/well) were seeded into each well and endothelial cell tubular networks formed within 4 hours of further incubation at 37°C. HTR-8/ SVneo cells (100 000 cells/well) were then added to each well with or without a low dose of TNF-α (0.5 ng/mL) together with methyldopa (5 μg/ mL), labetalol (0.5 μg/mL), hydralazine (10 μg/mL) or clonidine (1.0 μg/ mL) and co-cultured with the endothelial cellular networks. The control co-cultured cells had neither TNF-α nor medications added. After 24 hours of culture, the cells were retrieved from the cellular networks in Matrigel with Cell Recovery Solution (CRS) (In Vitro Technologies) for RNA extraction
Substance Class Chemical
Created
by admin
on Wed Jul 05 23:26:00 UTC 2023
Edited
by admin
on Wed Jul 05 23:26:00 UTC 2023
Record UNII
M4R0H12F6M
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
METHYLDOPA ANHYDROUS
Common Name English
J9.247I
Code English
ANHYDROUS METHYLDOPA
MART.  
Common Name English
(-)-.ALPHA.-METHYLDOPA
Common Name English
L-.ALPHA.-METHYL-3-(3,4)-DIHYDROXYPHENYLALANINE
Common Name English
L-TYROSINE, 3-HYDROXY-.ALPHA.-METHYL-
Systematic Name English
METHYLDOPA (LEVOROTATORY)
Common Name English
BAYER-1440L
Code English
(-)-METHYLDOPA
Systematic Name English
ANHYDROUS METHYLDOPA [MART.]
Common Name English
(-)-.ALPHA.-METHYL-3,4-DIHYDROXYPHENYLALANINE
Systematic Name English
L-.ALPHA.-METHYLDOPA
Common Name English
(2S)-2-AMINO-3-(3,4-DIHYDROXYPHENYL)-2-METHYLPROPANOIC ACID
Systematic Name English
.ALPHA.-METHYL-L-DOPA
Brand Name English
L-3-(3,4-DIHYDROXYPHENYL)-2-METHYLALANINE
Common Name English
Methyldopa [WHO-DD]
Common Name English
METHYL DOPA
Systematic Name English
methyldopa [INN]
Common Name English
METHYLDOPA [MI]
Common Name English
LEDERDOPA
Brand Name English
CARBIDOPA IMPURITY A [EP IMPURITY]
Common Name English
METHYLDOPA [HSDB]
Common Name English
NSC-169916
Code English
METHYLDOPA, ANHYDROUS
Common Name English
.ALPHA.-METHYL-L-3,4-DIHYDROXYPHENYLALANINE
Common Name English
(S)-(-)-.ALPHA.-METHYLDOPA
Common Name English
Classification Tree Code System Code
WHO-ATC C02AB01
Created by admin on Wed Jul 05 23:26:01 UTC 2023 , Edited by admin on Wed Jul 05 23:26:01 UTC 2023
NDF-RT N0000175554
Created by admin on Wed Jul 05 23:26:01 UTC 2023 , Edited by admin on Wed Jul 05 23:26:01 UTC 2023
WHO-ATC C02LB01
Created by admin on Wed Jul 05 23:26:01 UTC 2023 , Edited by admin on Wed Jul 05 23:26:01 UTC 2023
NDF-RT N0000009918
Created by admin on Wed Jul 05 23:26:01 UTC 2023 , Edited by admin on Wed Jul 05 23:26:01 UTC 2023
WHO-ATC C02AB
Created by admin on Wed Jul 05 23:26:01 UTC 2023 , Edited by admin on Wed Jul 05 23:26:01 UTC 2023
Code System Code Type Description
PUBCHEM
38853
Created by admin on Wed Jul 05 23:26:01 UTC 2023 , Edited by admin on Wed Jul 05 23:26:01 UTC 2023
PRIMARY
ECHA (EC/EINECS)
209-089-2
Created by admin on Wed Jul 05 23:26:01 UTC 2023 , Edited by admin on Wed Jul 05 23:26:01 UTC 2023
PRIMARY
RXCUI
1545996
Created by admin on Wed Jul 05 23:26:01 UTC 2023 , Edited by admin on Wed Jul 05 23:26:01 UTC 2023
PRIMARY RxNorm
EVMPD
SUB08867MIG
Created by admin on Wed Jul 05 23:26:01 UTC 2023 , Edited by admin on Wed Jul 05 23:26:01 UTC 2023
PRIMARY
INN
1110
Created by admin on Wed Jul 05 23:26:01 UTC 2023 , Edited by admin on Wed Jul 05 23:26:01 UTC 2023
PRIMARY
DAILYMED
M4R0H12F6M
Created by admin on Wed Jul 05 23:26:01 UTC 2023 , Edited by admin on Wed Jul 05 23:26:01 UTC 2023
PRIMARY
HSDB
218
Created by admin on Wed Jul 05 23:26:01 UTC 2023 , Edited by admin on Wed Jul 05 23:26:01 UTC 2023
PRIMARY
EPA CompTox
DTXSID5023295
Created by admin on Wed Jul 05 23:26:01 UTC 2023 , Edited by admin on Wed Jul 05 23:26:01 UTC 2023
PRIMARY
NCI_THESAURUS
C175729
Created by admin on Wed Jul 05 23:26:01 UTC 2023 , Edited by admin on Wed Jul 05 23:26:01 UTC 2023
PRIMARY
EVMPD
SUB26433
Created by admin on Wed Jul 05 23:26:01 UTC 2023 , Edited by admin on Wed Jul 05 23:26:01 UTC 2023
PRIMARY
MERCK INDEX
M7397
Created by admin on Wed Jul 05 23:26:01 UTC 2023 , Edited by admin on Wed Jul 05 23:26:01 UTC 2023
PRIMARY Merck Index
CAS
555-30-6
Created by admin on Wed Jul 05 23:26:01 UTC 2023 , Edited by admin on Wed Jul 05 23:26:01 UTC 2023
PRIMARY
FDA UNII
M4R0H12F6M
Created by admin on Wed Jul 05 23:26:01 UTC 2023 , Edited by admin on Wed Jul 05 23:26:01 UTC 2023
PRIMARY
DRUG BANK
DB00968
Created by admin on Wed Jul 05 23:26:01 UTC 2023 , Edited by admin on Wed Jul 05 23:26:01 UTC 2023
PRIMARY
NSC
169916
Created by admin on Wed Jul 05 23:26:01 UTC 2023 , Edited by admin on Wed Jul 05 23:26:01 UTC 2023
PRIMARY
WIKIPEDIA
METHYLDOPA
Created by admin on Wed Jul 05 23:26:01 UTC 2023 , Edited by admin on Wed Jul 05 23:26:01 UTC 2023
PRIMARY
CHEBI
61058
Created by admin on Wed Jul 05 23:26:01 UTC 2023 , Edited by admin on Wed Jul 05 23:26:01 UTC 2023
PRIMARY
Related Record Type Details
SOLVATE->ANHYDROUS
TARGET -> INHIBITOR
SALT/SOLVATE -> PARENT
SUBSTANCE->BASIS OF STRENGTH
Related Record Type Details
METABOLITE -> PARENT
ACTIVE IN RATS
METABOLITE -> PARENT
URINE
PARENT -> METABOLITE
URINE
METABOLITE -> PARENT
URINE
METABOLITE -> PARENT
METABOLITE -> PARENT
URINE
METABOLITE -> PARENT
Approximately 70 percent of the drug which is absorbed is excreted in the urine as methyldopa and its mono-0-sulfate conjugate
MAJOR
PLASMA; URINE
Related Record Type Details
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY